Australian clinicians and chemoprevention for women at high familial risk for breast cancer

Hereditary Cancer in Clinical Practice

Volumn 7, Issue 1, 2009, Pages

  Keogh, Louise A ^a   Hopper, John L ^a   Rosenthal, Doreen ^a   Phillips, Kelly Anne ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

RALOXIFENE; TAMOXIFEN;

ARTICLE; AUSTRALIA; BREAST CANCER; CANCER PREVENTION; CANCER RISK; CHEMOPROPHYLAXIS; CLINICAL EDUCATION; DRUG APPROVAL; EVIDENCE BASED MEDICINE; GENE MUTATION; HEALTH CARE COST; HETEROZYGOTE; HIGH RISK POPULATION; HORMONAL THERAPY; HUMAN; LEGAL ASPECT; MEDICAL SPECIALIST; OFF LABEL DRUG USE; OVARIECTOMY; PRACTICE GUIDELINE; RISK BENEFIT ANALYSIS;

EID: 79551568720     PISSN: 17312302     EISSN: 18974287     Source Type: Journal    
DOI: 10.1186/1897-4287-7-9     Document Type: Article

References (35)

1. Cuzick J, et al. Overview of the main outcomes in breast cancer prevention trials. Lancet 2003, 361:296-300. 10.1016/S0140-6736(03)12342-2, 12559863.
2. McKay A, Martin W, Latosinsky S. How should we inform women at higher risk of breast cancer about tamoxifen? An approach with a decision guide. Breast Cancer Res Treat 2005, 94:153-9. 10.1007/s10549-005-6932-6, 16261414.
3. Phillips K, et al. Risk-Reducing Surgery, Screening and Chemoprevention Practices Of BRCA1 And BRCA2 Mutation Carriers: A Prospective Cohort Study. Clin Genet. 2006, 70(3):198-206. 10.1111/j.1399-0004.2006.00665.x, 16922722.
4. Savage L. Researchers wonder why high-risk women are not taking chemoprevention drugs. J Natl Cancer Inst 2007, 99:913-4. 10.1093/jnci/djm032, 17565147.
5. Metcalfe K, et al. The use of preventive measures among healthy women who carry a BRCA1 or BRCA2 mutation. Familial Cancer 2005, 4:97-103. 10.1007/s10689-005-4215-3, 15951959.
6. Veronesi U, et al. Tamoxifen for the prevention of breast cancer: late results of the Italian randomized tamoxifen prevention trial among women with hysterectomy. J Natl Cancer Inst 2007, 99:727-37. 10.1093/jnci/djk154, 17470740.
7. Powles T, et al. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst 2007, 99:283-90. 10.1093/jnci/djk050, 17312305.
8. Fisher B, et al. Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 1998, 90:1371-88. 10.1093/jnci/90.18.1371, 9747868.
9. Cuzick J, et al. Long-term results of tamoxifen prophylaxis for breast cancer - 96 month follow-up of the randomized IBIS I-study. J Natl Cancer Inst 2007, 99:272-82. 10.1093/jnci/djk049, 17312304.
10. Veronesi U, Maisonneuve P, Decensi A. Tamoxifen: An enduring star. J Natl Cancer Inst 2007, 99:258-260. 10.1093/jnci/djk072, 17312297.
11. Nelson H, et al. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 2005, 143:362-79.
12. Vogel V, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene [STAR] P-2 trial. JAMA 2006, 295:2727-41. 10.1001/jama.295.23.joc60074, 16754727.
13. King M, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 2001, 286:2251-6. 10.1001/jama.286.18.2251, 11710890.
14. Keating N, et al. Physicians' experiences with BRCA1/2 testing in community settings. Journal of Clinical Oncology 2008, 26(35):5789-5796. 10.1200/JCO.2008.17.8053, 19001322.
15. Bober S, et al. Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors. J Clin Oncol 2004, 22:4951-57. 10.1200/JCO.2004.05.192, 15598980.
16. Cyrus-David M, Strom S. Chemoprevention of breast cancer with selective estrogen receptor modulators: views from broadly diverse groups of women with elevated risk for breast cancer. Psychooncology 2001, 10:521-33. 10.1002/pon.547, 11747064.
17. Slevin M, et al. Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses and general public. BMJ 1990, 300:1458-1460. 1663147, 2379006, 10.1136/bmj.300.6737.1458.
18. O'Connor A. Effects of framing and level of probability on patients' preferences for cancer chemotherapy. J Clin Epidemiol 1989, 42:119-126. 10.1016/0895-4356(89)90085-1, 2918321.
19. Peshkin B, et al. Tamoxifen as chemoprevention in BRCA1 and BRCA2 mutation carriers with breast cancer: a pilot survey of physicians. J Clin Oncol 2003, 21:4322-4328. 10.1200/JCO.2003.02.107, 14645421.
20. Kaplan C, et al. Factors affecting breast cancer risk reduction practices among California physicians. Prev Med 2005, 41:7-15. 10.1016/j.ypmed.2004.09.041, 15916987.
21. Liamputtong Rice P, Ezzy D. Qualitative Research Methods: A Health Focus. 1999, Melbourne: Oxford University Press.
22. Butow P, Lobb E. Analyzing the process and content of genetic counseling in familial breast cancer consultations. J Genetic Counselling 2004, 13:403-424.
23. Antill Y, Shanahan M, Phillips K. The integrated multidisciplinary clinic: A new model for the ongoing management of women at high genetic risk for breast and ovarian cancer. Cancer Forum 2005, 29:107-110.
24. Familial aspects of cancer: a guide to clinical practice. 1999, Biotext, NHMRC: Canberra.
25. Goldberg K. Specter seeks NCI explanation of delay in P-4 breast cancer prevention trial. The Cancer Letter 2007, 33:1-4.
26. Kathleen Cuningham Foundation Consortium for Research into Familial Breast cancer. 2007, cited 2007., http://www.kconfab.org/Index.shtml
27. Li W, et al. A role of estrogen/ERalpha signaling in BRCA1-associated tissue-specific tumor formation. Oncogene 2007, 26:7204-7212. 10.1038/sj.onc.1210527, 17496925.
28. Daidone M, et al. Estrogen receptor-beta expression in hereditary breast cancer. J Clin Oncol 2002, 20:3752-3. 10.1200/JCO.2002.99.116, 12202682.
29. Poole S, Dooley M. Off-label prescribing in oncology. Support Care Cancer 2004, 12:302-305. 10.1007/s00520-004-0593-6, 14986075.
30. Gazarian M, et al. Off-label use of medicines: consensus recommendations for evaluating appropriateness. MJA 2006, 185:544-548.
31. Kinsinger L, et al. Chemoprevention of breast cancer: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002, 137(1):59-69.
32. Levine M, et al. Chemoprevention of breast cancer. A joint guideline from the Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. CMAJ 2001, 164(12):1681-90. 81154, 11450210.
33. Chlebowski R, et al. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. J Clin Oncol 2002, 20(15):3328-43. 10.1200/JCO.2002.06.029, 12149307.
34. IBIS Investigators First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 2002, 360:817-24. 10.1016/S0140-6736(02)09962-2, 12243915, IBIS Investigators.
35. Metcalfe K, et al. Development and testing of a decision aid for breast cancer prevention for women with a BRCA1 or BRCA2 mutation. Clin Genet 2007, 72:208-17. 10.1111/j.1399-0004.2007.00859.x, 17718858.